Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Electron. j. biotechnol ; 32: 1-5, Mar. 2018. ilus
Article in English | LILACS | ID: biblio-1022489

ABSTRACT

Background: TRF2 (telomeric repeat binding factor 2) is an essential component of the telomere-binding protein complex shelterin. TRF2 induces the formation of a special structure of telomeric DNA and counteracts activation of DNA damage-response pathways telomeres. TRF2 has a poorly characterized linker region (udTRF2) between its homodimerization and DNA-binding domains. Some lines of evidence have shown that this region could be involved in TRF2 interaction with nuclear lamina. Results: In this study, the fragment of the TERF2 gene encoding udTRF2 domain of telomere-binding protein TRF2 was produced by PCR and cloned into the pET32a vector. The resulting plasmid pET32a-udTRF2 was used for the expression of the recombinant udTRF2 in E. coli RosettaBlue (DE3). The protein was isolated and purified using ammonium sulfate precipitation followed by ion-exchange chromatography. The purified recombinant protein udTRF2 was injected into guinea pigs to generate polyclonal antibodies. The ability of anti-udTRF2 antibodies to bind endogenous TRF2 in human skin fibroblasts was tested by western blotting and immunofluorescent staining. Conclusions: In this study, the recombinant protein udTRF2 and antibodies to it were generated. Both protein and antibodies will provide a useful tool for investigation of the functions of the udTRF2 domain and its role in the interaction between TRF2 and nuclear lamina.


Subject(s)
Animals , Guinea Pigs , Telomeric Repeat Binding Protein 2/metabolism , Antibodies/metabolism , Plasmids , Recombinant Proteins/metabolism , Immunohistochemistry , Blotting, Western , Chromosomes , Cloning, Molecular , Nuclear Lamina , Telomeric Repeat Binding Protein 2/genetics , Immunoprecipitation , DNA-Binding Proteins/metabolism , Escherichia coli/metabolism , Antibodies/isolation & purification , Antibody Formation , Nucleoproteins
2.
Biol. Res ; 47: 1-7, 2014. graf, tab
Article in English | LILACS | ID: biblio-950757

ABSTRACT

BACKGROUND: Telomeres are protective caps consisted of specific tandem repeats (5'-TTAGGG-3'). Shortening of telomeres at each cell division is known as "mitotic clock" of the cells, which renders telomeres as important regulators of lifespan. TRF2 is one of the critical members of shelterin complex, which is a protein complex responsible from the preservation of cap structure, and loss or mutation of TRF2 results in DNA damage, senescence or apoptosis. Since cancer is frequently associated with aberrant cell cycle progression, defective DNA repair or apoptosis pathways, TRF2 could be one likely candidate for cancer therapy. Here we investigated the prognostic role of TRF2 levels in cervical cancer patients. Fold-induction rates were evaluated with respect to median values after real-time PCR analysis. Overall survival, distant disease-free and local recurrence-free survival rates were calculated using Kaplan-Meier long rank test. RESULTS: Both five year overall- and disease-free survival rates were longer in patients with higher TRF2 expression compared to lower expression, but results were not statistically significant (69.2% vs 28.9%, respectively). Mean local recurrence-free survivals (LRF) were very close ( 58.6, CI: 44.3-72.9 vs 54.5, CI: 32.1-76.9 months) for high and low expressions, respectively. Cumulative proportion of LRF at the end of five year period was 76.9% for high and 57.1% for low TRF2 expression (P = 0.75). Statistically significant difference was found between survival ratios and Bcl-xL and p53 gene expressions, but not with TRF2. A respectable correlation between TRF2 expression and apoptosis along with distant metastasis was noted (P = 0.045 and 0.036, respectively). Additionally, high TRF2 expression levels had a positive impact in five year survival rate of stage IIIB-IVA patients (P = 0.04). CONCLUSIONS: Our results support the role of TRF2 in apoptosis and imply a positive relation with distant metastases and survival in advanced stage patients. The remarkable difference in survival periods of patients with different TRF2 expressions suggest that TRF2 may be a candidate factor to estimate survival for cervical cancer, a preliminary observation which should further be verified with a larger cohort.


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/mortality , Telomere/metabolism , Telomeric Repeat Binding Protein 2/metabolism , Recurrence , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/pathology , Survival Rate , Tumor Suppressor Protein p53/analysis , Apoptosis/genetics , Statistics, Nonparametric , Disease-Free Survival , In Situ Nick-End Labeling , bcl-X Protein/analysis , Kaplan-Meier Estimate , Real-Time Polymerase Chain Reaction , Neoplasm Staging
SELECTION OF CITATIONS
SEARCH DETAIL